New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
10:01 EDTAEGN, RUSHA, RXN, QSII, PHG, PNR, TV, LLY, CTCM, BRO, TTMOn The Fly: Analyst Downgrade Summary
Aegion (AEGN) downgraded to Neutral from Buy at Sidoti... Brown & Brown (BRO) downgraded to Neutral from Buy at Compass Point... CTC Media (CTCM) downgraded to Underperform from Neutral at Credit Suisse... Eli Lilly (LLY) downgraded to Neutral from Buy at MKM Partners... Grupo Televisa (TV) downgraded to Underperform from Neutral at BofA/Merrill... Pentair (PNR) downgraded to Neutral from Outperform at Wedbush... Philips (PHG) downgraded to Sector Perform from Outperform at RBC Capital... Quality Systems (QSII) downgraded to Underweight from Equal Weight at Morgan Stanley... Rexnord (RXN) downgraded at BofA/Merrill... Rush Enterprises (RUSHA) downgraded to Equal Weight from Overweight at Stephens... Tata Motors (TTM) downgraded to Neutral from Outperform at Credit Suisse.
News For AEGN;BRO;CTCM;LLY;TV;PNR;PHG;QSII;RXN;RUSHA;TTM From The Last 14 Days
Check below for free stories on AEGN;BRO;CTCM;LLY;TV;PNR;PHG;QSII;RXN;RUSHA;TTM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2014
09:41 EDTTTMTata Motors upgraded to Buy from Hold at Jefferies
08:32 EDTBROBrown & Brown files automatic mixed securities shelf
Subscribe for More Information
August 31, 2014
14:07 EDTRXNVertical Research Partners to hold a conference
Subscribe for More Information
14:00 EDTQSIIFBR Capital to hold a conference
Healthcare Conference to be held in Boston on September 3.
August 28, 2014
07:31 EDTLLYEli Lilly management to meet with Deutsche Bank
Subscribe for More Information
August 27, 2014
09:53 EDTLLYOn The Fly: Analyst Initiation Summary
Bristol-Myers (BMY) initiated with a Hold at Deutsche Bank... ASML (ASML) initiated with a Hold at Stifel... Akamai (AKAM) initiated with an Outperform at RW Baird... Concur (CNQR) initiated with a Neutral at DA Davidson... CyrusOne (CONE) initiated with a Neutral at Citigroup... Eli Lilly (LLY) initiated with a Buy at Deutsche Bank... Garmin (GRMN) initiated with a Neutral at RW Baird... Merck (MRK) initiated with a Hold at Deutsche Bank... NetSuite (N) initiated with a Buy at DA Davidson... Oracle (ORCL) initiated with a Neutral at DA Davidson... Oxford Industries (OXM) initiated with a Buy at Wunderlich... Pfizer (PFE) initiated with a Buy at Deutsche Bank... ServiceNow (NOW) initiated with a Buy at DA Davidson... Workday (WDAY) initiated with a Neutral at DA Davidson... MannKind (MNKD) initiated with a Buy at Jefferies... STMicroelectronics (STM) initiated with an Underperform at Credit Suisse... Kirkland's (KIRK) initiated with an Outperform at Barrington.
06:42 EDTLLYEli Lilly initiated with a Buy at Deutsche Bank
Target $71.
August 26, 2014
13:49 EDTPHGIndia switching all streetlights to LED, Times of India reports
Subscribe for More Information
09:07 EDTLLYEli Lilly announces Jardiance available in U.S. pharmacies
Subscribe for More Information
05:49 EDTQSIINextGen Healthcare partners with North Carolina Pediatric Associates
Subscribe for More Information
August 21, 2014
07:12 EDTLLYEli Lilly announces results from pivotal UNCOVER studies for ixekizumab
Eli Lilly announces that its investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies. Patients treated with both dosing regimens of ixekizumab had significantly greater levels of skin clearance compared to placebo and to etanercept at the 12-week endpoint. Skin clearance was measured by standard primary endpoints for psoriasis studies: the Psoriasis Area and Severity Index and the Static Physician Global Assessment. For patients treated with ixekizumab either every four weeks or every two weeks, between 78 to 90 percent of patients achieved at least a 75 percent reduction in PASI score at 12 weeks. Additionally, 31 to 41 percent of these patients achieved PASI 100, or clear skin, at week 12. For comparison, between 5 to 7 percent of patients treated with etanercept in the UNCOVER-2 and 3 studies achieved PASI 100. Adverse events were comparable for patients receiving ixekizumab in the 12-week, randomized control portion across all three studies.
August 19, 2014
08:31 EDTTVGrupo Televisa price target raised to $45 from $40 at Maxim
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use